Masimo Co. (NASDAQ:MASI) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Masimo Co. (NASDAQ:MASI - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $191.40.

Several analysts have recently commented on MASI shares. Piper Sandler increased their price objective on Masimo from $180.00 to $210.00 and gave the company an "overweight" rating in a report on Wednesday, December 18th. Raymond James increased their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research report on Friday, December 27th. Stifel Nicolaus reaffirmed a "buy" rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday, January 22nd. Finally, Wells Fargo & Company lifted their price objective on Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th.

Institutional Investors Weigh In On Masimo

A number of institutional investors have recently made changes to their positions in MASI. Jones Financial Companies Lllp acquired a new position in shares of Masimo in the 4th quarter valued at $27,000. UMB Bank n.a. raised its position in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 123 shares during the last quarter. Trust Co. of Vermont bought a new stake in shares of Masimo during the fourth quarter valued at about $33,000. Blue Trust Inc. boosted its stake in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Price Performance

MASI traded down $7.25 during trading on Thursday, reaching $169.96. The stock had a trading volume of 603,597 shares, compared to its average volume of 401,265. The business has a 50-day moving average of $172.90 and a 200-day moving average of $151.29. Masimo has a one year low of $101.61 and a one year high of $184.51. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock has a market cap of $9.10 billion, a PE ratio of 117.21 and a beta of 1.02.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.